Filing Details
- Accession Number:
- 0000899243-19-028831
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-12-10 16:02:33
- Reporting Period:
- 2019-12-06
- Accepted Time:
- 2019-12-10 16:02:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1731831 | Eidos Therapeutics Inc. | EIDX | Pharmaceutical Preparations (2834) | 463733671 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1758363 | Cameron Turtle | C/O Eidos Therapeutics, Inc. 101 Montgomery Street, Suite 2000 San Francisco CA 94104 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-12-06 | 10,000 | $13.20 | 95,155 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-12-06 | 400 | $56.84 | 94,755 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-06 | 700 | $58.28 | 94,055 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-12-06 | 8,900 | $59.43 | 85,155 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2019-12-06 | 10,000 | $0.00 | 10,000 | $13.20 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 95,000 | 2028-11-05 | No | 4 | M | Direct |
Footnotes
- Represents the weighted average sale price of the shares sold from $56.73 to $56.95 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported in footnotes 1 through 3.
- Represents the weighted average sale price of the shares sold from $58.00 to $58.78 per share.
- Represents the weighted average sale price of the shares sold from $59.07 to $60.00 per share.
- 25% of the shares subject to this option vested and became exercisable on November 5, 2019 and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Billionaire Hedge Funds
